More than 10,000 scientific publications containing EUDRAGIT
EUDRAGIT polymers have been used as coatings to create more effective drugs for 70 years. Over the decades, the portfolio of methacrylate polymers has established itself as the industry standard with more than 23,000 patents and 10,000 scientific publications mentioning the EUDRAGIT brand.
With its long-standing experience in functional excipients, formulation and application services, Evonik provides EUDRAGIT polymers as key ingredients in multi-component systems that are tailored to a unique and specific customer need. These system solutions are driving a transformation within Evonik’s life sciences division, Nutrition & Care, which is leveraging its expertise in biosolutions to increase its share of system solutions to 70 percent by 2032.
“From baby boomers to generation alpha, we are proud to have been enabling pharmaceutical innovation with EUDRAGIT® from day one, improving health outcomes around the world,” said Thomas Riermeier, head of the Health Care business line at Evonik.
EUDRAGIT is the industry’s preferred portfolio of functional polymers for use with oral drug products. The breadth, versatility and history of EUDRAGIT, combined with Evonik’s range of drug delivery technologies, formulation and cGMP manufacturing services, provides pharmaceutical companies with unrivalled safety, supply security and functional reliability for their oral solid dosage forms.
“Nearly everyone you know will have come into contact with EUDRAGIT at some point in their lives,” said Paul Spencer, head of Drug Delivery & Products at Evonik. “With a growing and aging population, we look forward to continuing to innovate these polymers into next-generation solutions, such as the recently launched EUDRACAP® which is fast becoming a leading choice for enteric capsule protection.”
Register Now to Attend Agrochem Summit 2024 on Friday, December 13th, 2024 at The Park, New Delhi
Subscribe To Our Newsletter & Stay Updated